We were delighted to speak with Prof. Tina Vilsbøll (University of Copenhagen, Copenhagen, Denmark) about the approval of semaglutide and the impact on the GLP-1RA landscape, and the movement towards individualizing care in patients with type 2 diabetes.
Questions
- What has been the impact of the approval of oral semaglutide in the GLP-1RA landscape? (0:15)
- How have recent advances impacted on the opportunity for individualised diabetes care? (1:19)
- What factors should be considered in tailoring oral GLP-1RA therapy to the individual? (2:29)
- How do you see the role of oral GLP-1RAs evolving in the future? (3:42)
Disclosures: Prof. Tina Vilsbøll reports financial disclosures with the following: Amgen, AZ, BMS, Boehringer, Gielad, Lilly, Novo, Sanofi, Sunpharma.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the European Association for the Study of Diabetes (EASD) 2020.
